drugset / Trial / NCT00382629
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine if BHT-3009 decreases inflammation (measured by gadolinium enhancing MRI lesions) in the brains of people with relapsing remitting multiple sclerosis.
Timeline
- Start
- 2006-02
- Primary completion
- —
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BHT-3009 | Vaccine | 0.5 mg | — |
| Subject | BHT-3009 | Vaccine | 1.5 mg | — |